Federal Register / Vol. 86, No. 146 / Tuesday, August 3, 2021 / Notices 41871 

correcting records on the SAVE website 

at www.uscis.gov/save. 

[FR Doc. 2021–16481 Filed 7–30–21; 8:45 am] 

BILLING CODE 9111–97–P 

DEPARTMENT OF THE INTERIOR 

Fish and Wildlife Service 

[FWS–R1–ES–2021–N005; 

FXES11130100000–212–FF01E00000] 

Endangered and Threatened Wildlife 

and Plants; Draft Recovery Plan for 

White Bluffs Bladderpod 

AGENCY: Fish and Wildlife Service, 

Interior. 

ACTION: Notice of availability; request 

for review and public comment. 

SUMMARY: We, the U.S. Fish and 

Wildlife Service, announce the 

availability of the Draft Recovery Plan 

for White Bluffs Bladderpod (Physaria 

douglasii subsp. tuplashensis), listed as 

threatened under the Endangered 

Species Act, and endemic to Franklin 

County, Washington. We request review 

and comment on this draft recovery 

plan from Federal, State, and local 

agencies; Native American Tribes; and 

the public. 

DATES: To ensure consideration, 

comments on the draft recovery plan 

must be received on or before October 

4, 2021. However, we will accept 

information about any species at any 

time. 

ADDRESSES:

Document availability: Obtain the 

recovery plan by the following method. 

• Internet: http://www.fws.gov/ 

endangered/species/recovery-plans.html 

or http://www.fws.gov/pacific/ 

ecoservices/endangered/recovery/ 

plans.html. 

Comment submission: You may 

submit written comments and materials 

by one of the following methods: 

• U.S. mail: Jeff Krupka, Central 

Washington Field Office, at the above 

U.S. mail address. 

• Fax: 360–753–9405. 

• Email: WFWO_LR@fws.gov. 

FOR FURTHER INFORMATION CONTACT: Brad 

Thompson, State Supervisor, U.S. Fish 

and Wildlife Service, Washington Fish 

and Wildlife Office, at the above U.S. 

mail address; telephone 360–753–4652. 

If you use a telecommunications device 

for the deaf, call the Federal Relay 

Service at 1–800–877–8339. 

SUPPLEMENTARY INFORMATION: We, the 

U.S. Fish and Wildlife Service (Service), 

announce the availability of the Draft 

Recovery Plan for White Bluffs 

Bladderpod (Physaria douglasii subsp. 

tuplashensis). The subspecies, listed as 

threatened under the Endangered 

Species Act of 1973, as amended (Act; 

16 U.S.C. 1531 et seq.), is a plant 

endemic to the White Bluffs of Franklin 

County, Washington. The draft recovery 

plan includes specific goals, objectives, 

and criteria that should be met prior to 

our consideration of removing the 

species from the Federal List of 

Endangered and Threatened Plants. We 

request review and comment on this 

draft recovery plan from Federal, State, 

and local agencies; Native American 

Tribes; and the public. 

Background 

The White Bluffs bladderpod is a 

short-lived, herbaceous perennial that 

occurs intermittently in a narrow, linear 

strip about 15 kilometers (9.3 miles) 

long, along sparsely vegetated upper 

and top exposures of the White Bluffs in 

eastern Washington State. This plant is 

closely associated with highly alkaline, 

cemented calcium carbonate soil along 

the Columbia River in the State of 

Washington. In April 2013, and as 

reaffirmed in December 2013, the White 

Bluffs bladderpod was listed as a 

threatened species pursuant to the Act 

(78 FR 23983; April 23, 2013; 78 FR 

76995; December 20, 2013). 

Recovery Planning Process 

Recovery of endangered and 

threatened animals and plants is a 

primary goal of our endangered species 

program. To help guide the recovery 

effort, we prepare recovery plans for 

most listed species. Recovery plans 

describe actions considered necessary 

for conservation of the species, establish 

criteria for downlisting or delisting, and 

estimate time and cost for implementing 

recovery measures. 

Recovery Planning and Implementation 

The Service recently revised its 

approach to recovery planning, and is 

now using a process termed recovery 

planning and implementation (RPI) (see 

https://www.fws.gov/endangered/esalibrary/pdf/RPI.pdf). The RPI approach 

is intended to reduce the time needed 

to develop and implement recovery 

plans, increase recovery plan relevancy 

over a longer timeframe, and add 

flexibility to recovery plans so they can 

be adjusted to new information or 

circumstances. Under RPI, a recovery 

plan includes the statutorily required 

elements under section 4(f) of the Act 

(objective and measurable recovery 

criteria, site-specific management 

actions, and estimates of time and 

costs), a concise introduction, and our 

strategy for how we plan to achieve 

species recovery. The RPI recovery plan 

is supported by two supplementary 

documents: A species status assessment 

or biological report, which describes the 

best available scientific information 

related to the biological needs of the 

species and assessment of threats; and 

the recovery implementation strategy, 

which details the particular near-term 

activities needed to implement the 

recovery actions identified in the 

recovery plan. Under this approach, we 

can more nimbly incorporate new 

information on species biology or 

details of recovery implementation by 

updating these supplementary 

documents without concurrent revision 

of the entire recovery plan, unless 

changes to statutorily required elements 

are necessary. 

Recovery Plan Components 

The primary recovery strategy for the 

White Bluffs bladderpod is to increase 

the capability of populations to 

withstand stochastic events; to establish 

new populations as possible and 

appropriate; to provide a safety margin 

against catastrophic events; and to 

increase the ecological and/or genetic 

diversity of the subspecies. Recovery 

will hinge on two types of strategies, 

direct and indirect, to improve habitat, 

reduce threats, and preserve or enhance 

the ability of individuals to survive and 

reproduce in the range of conditions 

they are likely to experience. 

We may initiate an assessment of 

whether recovery has been achieved and 

delisting is warranted when the 

recovery criteria have been met, 

including once a second population has 

been discovered or established on 

conserved lands and is managed in a 

way that is compatible with White 

Bluffs bladderpod conservation. All 

populations must be self-sustaining. 

Request for Public Comments 

Section 4(f) of the Act requires us to 

provide public notice and an 

opportunity for public review and 

comment during recovery plan 

development. It is also our policy to 

request peer review of recovery plans 

(59 FR 34270; July 1, 1994). In an 

appendix to the approved final recovery 

plan, we will summarize and respond to 

the issues raised during public comment 

and peer review. Substantive comments 

may or may not result in changes to the 

recovery plan. Comments regarding 

recovery plan implementation will be 

forwarded as appropriate to Federal and 

other entities so that they can be taken 

into account during the course of 

implementing recovery actions. 

We will consider all comments we 

receive by the date specified in DATES

prior to final approval of the plan. 


jbell on DSKJLSW7X2PROD with NOTICES
41872 Federal Register / Vol. 86, No. 146 / Tuesday, August 3, 2021 / Notices 

Public Availability of Comments 

Before including your address, phone 

number, email address, or other 

personal identifying information in your 

comment, you should be aware that 

your entire comment—including your 

personal identifying information—may 

be made publicly available at any time. 

While you can ask us in your comment 

to withhold your personal identifying 

information from public review, we 

cannot guarantee that we will be able to 

do so. 

Authority 

The authority for this action is section 

4(f) of the Endangered Species Act of 

1973, as amended (16 U.S.C. 1531 et 

seq.). 

Robyn Thorson, 

Regional Director, U.S. Fish and Wildlife 

Service. 

[FR Doc. 2021–16521 Filed 8–2–21; 8:45 am] 

BILLING CODE 4333–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–874] 

Bulk Manufacturer of Controlled 

Substances Application: Purisys, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Purisys, LLC has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 4, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

October 4, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on June 30, 2021, 1550 

Olympic Drive, Athens, Georgia 30601– 

1602, applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled 

substance Drug code Schedule 

Opium, powdered.9639 II 

Opium, granulated.9640 II 

The company plans to bulk 

manufacture the listed controlled 

substances as Active Pharmaceutical 

Ingredient (API) for distribution to its 

customers. No other activities for these 

drug codes are authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–16500 Filed 8–2–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–873] 

Bulk Manufacturer of Controlled 

Substances Application: Cerilliant 

Corporation 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Cerilliant Corporation has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTAL INFORMATION listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 4, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

October 4, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on June, 24, 2021, 

Cerilliant Corporation, 811 Paloma 

Drive, Suite A, Round Rock, Texas 

78665–2402, applied to be registered as 

a bulk manufacturer of the following 

basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

3-Fluoro-N-methylcathinone (3-FMC) .............................................................................................................................. 1233 I 

Cathinone ........................................................................................................................................................................ 1235 I 

Methcathinone ................................................................................................................................................................. 1237 I 

4-Fluoro-N-methylcathinone (4-FMC) .............................................................................................................................. 1238 I 

Pentedrone (a-methylaminovalerophenone) ................................................................................................................... 1246 I 

Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 1248 I 

4-Methyl-N-ethylcathinone (4-MEC) ................................................................................................................................ 1249 I 

Naphyrone ....................................................................................................................................................................... 1258 I 

N-Ethylamphetamine ....................................................................................................................................................... 1475 I 

N,N-Dimethylamphetamine .............................................................................................................................................. 1480 I 

Fenethylline ..................................................................................................................................................................... 1503 I 

Aminorex .......................................................................................................................................................................... 1585 I 

4-Methylaminorex (cis isomer) ........................................................................................................................................ 1590 I 

Gamma Hydroxybutyric Acid ........................................................................................................................................... 2010 I 

Methaqualone .................................................................................................................................................................. 2565 I 

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ................................................................................................... 6250 I 

SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................. 7008 I 

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ............. 7010 I 

5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................. 7011 I 

AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ...................... 7012 I 

FUB-144 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone) ............................................... 7014 I 

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ....................................................................................................................... 7019 I 

MDMB-FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ....................... 7020 I 


jbell on DSKJLSW7X2PROD with NOTICES